Athersys, Inc. (ATHX): Price and Financial Metrics

Athersys, Inc. (ATHX): $0.02

0.00 (-13.93%)

POWR Rating

Component Grades








Add ATHX to Watchlist
Sign Up

Industry: Biotech




#189 of 387

in industry

ATHX Price/Volume Stats

Current price $0.02 52-week high $1.99
Prev. close $0.03 52-week low $0.02
Day low $0.02 Volume 256,100
Day high $0.03 Avg. volume 1,527,474
50-day MA $0.08 Dividend yield N/A
200-day MA $0.65 Market Cap 1.49M

ATHX Stock Price Chart Interactive Chart >


  • ATHX scores best on the Growth dimension, with a Growth rank ahead of 90.65% of US stocks.
  • The strongest trend for ATHX is in Sentiment, which has been heading down over the past 76 days.
  • ATHX's current lowest rank is in the Stability metric (where it is better than 8.75% of US stocks).

ATHX Stock Summary

  • ATHX's price/sales ratio is 46.55; that's higher than the P/S ratio of 96.91% of US stocks.
  • Revenue growth over the past 12 months for ATHERSYS INC comes in at -98.65%, a number that bests merely 0.67% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ATHX comes in at -294.23% -- higher than that of just 2.33% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ATHERSYS INC are IKNA, SYRS, SPRB, STTK, and IPSC.
  • Visit ATHX's SEC page to see the company's official filings. To visit the company's web site, go to

ATHX Valuation Summary

  • In comparison to the median Healthcare stock, ATHX's price/sales ratio is 1102.56% higher, now standing at 46.9.
  • ATHX's price/earnings ratio has moved up 0.1 over the prior 199 months.

Below are key valuation metrics over time for ATHX.

Stock Date P/S P/B P/E EV/EBIT
ATHX 2023-10-06 46.9 -0.2 -0.1 -0.6
ATHX 2023-10-05 51.0 -0.2 -0.2 -0.6
ATHX 2023-10-04 68.3 -0.3 -0.2 -0.7
ATHX 2023-10-03 68.3 -0.3 -0.2 -0.7
ATHX 2023-10-02 65.5 -0.3 -0.2 -0.7
ATHX 2023-09-29 66.9 -0.3 -0.2 -0.7

ATHX Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -77.35%.
  • The 5 year cash and equivalents growth rate now stands at 2.35%.
  • The 2 year cash and equivalents growth rate now stands at -33.33%.
Over the past 49 months, ATHX's revenue has gone down $17,933,000.

The table below shows ATHX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.015 -66.324 -81.244
2022-06-30 10.742 -75.597 -83.752
2022-03-31 8.426 -79.26 -82.703
2021-12-31 5.514 -76.185 -86.955
2021-09-30 6.062 -74.126 -87.45
2021-06-30 1.356 -74.157 -93.816

ATHX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATHX has a Quality Grade of C, ranking ahead of 38.11% of graded US stocks.
  • ATHX's asset turnover comes in at 0.02 -- ranking 368th of 682 Pharmaceutical Products stocks.
  • INFI, NLTX, and LCTX are the stocks whose asset turnover ratios are most correlated with ATHX.

The table below shows ATHX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.020 1 7.687
2021-03-31 0.020 1 6.179
2020-12-31 0.023 1 6.796
2020-09-30 0.008 1 7.038
2020-06-30 0.000 1 6.688
2020-03-31 0.092 1 6.754

ATHX Price Target

For more insight on analysts targets of ATHX, see our ATHX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.75 Average Broker Recommendation 1.38 (Strong Buy)

Athersys, Inc. (ATHX) Company Bio

Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. The company was founded in 1995 and is based in Cleveland, Ohio.

ATHX Latest News Stream

Event/Time News Detail
Loading, please wait...

ATHX Latest Social Stream

Loading social stream, please wait...

View Full ATHX Social Stream

Latest ATHX News From Around the Web

Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

Here are the best longevity stocks to consider.

Matthew Farley on InvestorPlace | October 17, 2023

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

CLEVELAND, October 16, 2023--Athersys, Inc. (Nasdaq: ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distr

Yahoo | October 16, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about!

William White on InvestorPlace | October 11, 2023

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

CLEVELAND, October 10, 2023--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients

Yahoo | October 10, 2023

20 Foods Consumed By Longest Living People Every Day

In this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […]

Yahoo | October 4, 2023

Read More 'ATHX' Stories Here

ATHX Price Returns

1-mo -23.08%
3-mo -95.58%
6-mo -98.06%
1-year -96.94%
3-year -99.96%
5-year -99.96%
YTD -97.62%
2022 -96.28%
2021 -48.42%
2020 42.28%
2019 -14.58%
2018 -20.44%

Continue Researching ATHX

Here are a few links from around the web to help you further your research on Athersys Inc's stock as an investment opportunity:

Athersys Inc (ATHX) Stock Price | Nasdaq
Athersys Inc (ATHX) Stock Quote, History and News - Yahoo Finance
Athersys Inc (ATHX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!